2-[(4-{2-[4-(1H-imidazol-1-yl)phenoxy]ethyl}phenoxy)methyl]benzoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[(4-{2-[4-(1H-imidazol-1-yl)phenoxy]ethyl}phenoxy)methyl]benzoic acid
• 英文别名: (4-{2-[4-(1H-imidazol-1-yl)phenoxy]ethyl}-phenoxymethyl]benzoic acid；2-[[4-[2-(4-imidazol-1-ylphenoxy)ethyl]phenoxy]methyl]benzoic acid
• 化学式: C₂₅H₂₂N₂O₄
• 分子量: 414.461
• InChiKey: BCNUNEOYFPZMQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  73.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  methyl 2-[(4-{2-[4-(1H-imidazol-1-yl)phenoxy]ethyl}phenoxy)methyl]benzoate 在 lithium hydroxide 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 0.12h， 以4.7%的产率得到2-[(4-{2-[4-(1H-imidazol-1-yl)phenoxy]ethyl}phenoxy)methyl]benzoic acid
  参考文献：
  名称：

  [EN] BENZOIC ACID DERIVATIVES AS MODULATORS OF PPAR ALPHA AND GAMMA
  [FR] DERIVES D'ACIDE BENZOIQUE UTILISES EN TANT QUE MODULATEURS DE PPAR ALPHA AND GAMMA

  摘要：

  式（I）的化合物，其中R1代表芳基，可选地被杂环基取代，或者被芳基取代的杂环基，其中每个芳基或杂环基可选地被取代；在苯环中的3位或4位之一连接有组-(CH2)m-T-(CH2)n-U-(CH2)p-，如式（I）中的数字所示，并表示从以下一个或多个中选择的组：O(CH2)2，O(CH2)3，NC(O)NR4(CH2)2，CH2S(O2)NR5(CH2)2，CH2N(R6)C(O)CH2，(CH2)2N(R6)C(O)(CH2)2，C(O)NR7CH2，C(O)NR7(CH2)2和CH2N(R6)C(O)CH2O；V代表O，S，NR8或单键；q代表1、2或3；W代表O，S，N(R9)C(O)，NR10或单键；R2代表卤素，可选地被一个或多个氟取代的C1-4烷基，可选地被一个或多个氟取代的C1-4烷氧基，C1-4酰基，芳基，芳基C1-4烷基，CN或NO2；r代表0、1、2或3；R3代表卤素，可选地被一个或多个氟取代的C1-4烷基，可选地被一个或多个氟取代的C1-4烷氧基，C1-4酰基，芳基，芳基C1-4烷基或CN；s代表0、1、2或3；R4、R5、R6、R7、R8、R9和R10独立地代表H，C1-10烷基，芳基或芳基C1-4烷基，或者当m为0且T代表N(R6)C(O)或(R5)NS(O2)时，R1和R6或R1和R5与它们连接的氮原子一起代表杂芳基；以及其药学上可接受的盐，制备这种化合物的方法，它们在治疗与胰岛素抵抗相关的临床病症中的用途，它们的治疗用途的方法和含有它们的药物组合物。

  公开号：

  WO2004000295A1

文献信息

• Benzoic acid derivatives as modulators of ppar alpha and gamma
  申请人：Li Lanna

  公开号：US20050267149A1

  公开（公告）日：2005-12-01

  A compound of formula (I) wherein R 1 represents aryl optionally substituted by a heterocyclic group or a heterocyclic group optionally substituted by aryl wherein each aryl or heterocyclic group is optionally substituted; the group —CH 2 ) m -T-(CH 2 ) n —U—(CH 2 ) p — is attached at either the 3 or 4 position in the phenyl ring as indicated by the numbers in formula (I) and represents a group selected from one or more of the following: O(CH 2 ) 2 , O(CH 2 ) 3 , NC(O)NR 4 (CH 2 ) 2 , CH 2 S(O 2 )NR 5 (CH 2 ) 2 , CH 2 N(R 6 )C(O)CH 2 , (CH 2 ) 2 N(R 6 )C(O)(CH 2 ) 2 , C(O)NR 7 CH 2 , C(O)NR 7 (CH 2 ) 2 , and CH 2 N(R 6 )C(O)CH 2 O; V represents O, S, NR 8 , or a single bond; q represents 1, 2, or 3; W represents O, S, N(R 9 )C(O), NR 10 , or a single bond; R 2 represents halo, a C 1-4 alkyl group which is optionally substituted by one or more fluoro, a C 1-4 alkoxy group which is optionally substituted by one or more fluoro, a C 1-4 acyl group, aryl, an aryl C 1-4 alkyl group, CN or NO 2 ; r represents 0, 1, 2 or 3; R 3 represents halo, a C 1-4 alkyl group which is optionally substutited by one or more fluoro, a C 1-4 alkoxy group which is optionally substituted by one or more fluoro, a C 1-4 acyl group, aryl, an aryl C 1-4 alkyl group, or CN; s represents 0, 1, 2 or 3; and R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 independently represent H, a C 1-10 alkyl group, aryl or an aryl C 1-4 alkyl group or when m is 0 and T represents a group N(R 6 )C(O) or a group (R 5 )NS(O 2 ) then R 1 and R or R 1 and R 5 thogether with the nitrogen atom to which they are attached represent a heteroaryl group; with provisos and pharmaceutically acceptable salts thereof, processes for preparing such compouds, their utility in treating clinical conditions associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.

  化合物的式子为(I)，其中R1表示芳基，可选地被杂环基取代，或者是可选地被芳基取代的杂环基，其中每个芳基或杂环基都可以被取代; 在苯环中，基团—CH2)m-T-(CH2)n—U—(CH2)p—以式(I)中的数字所示的3或4位置附着，并表示从以下一种或多种中选择的基团：O(CH2)2、O(CH2)3、NC(O)NR4(CH2)2、CH2S(O2)NR5(CH2)2、CH2N(R6)C(O)CH2、(CH2)2N(R6)C(O)(CH2)2、C(O)NR7CH2、C(O)NR7(CH2)2和CH2N(R6)C(O)CH2O; V表示O、S、NR8或单键; q表示1、2或3; W表示O、S、N(R9)C(O)、NR10或单键; R2表示卤素、可选地被一个或多个氟代取代的C1-4烷基、可选地被一个或多个氟代取代的C1-4烷氧基、C1-4酰基、芳基、芳基C1-4烷基、CN或NO2; r表示0、1、2或3; R3表示卤素、可选地被一个或多个氟代取代的C1-4烷基、可选地被一个或多个氟代取代的C1-4烷氧基、C1-4酰基、芳基、芳基C1-4烷基或CN; s表示0、1、2或3; R4、R5、R6、R7、R8、R9和R10独立地表示H、C1-10烷基、芳基或芳基C1-4烷基，或者当m为0且T表示一个基团N(R6)C(O)或一个基团(R5)NS(O2)时，R1和R或R1和R5与它们附着的氮原子一起表示杂芳基; 具有附加条件和药学上可接受的盐，制备这种化合物的过程，它们在治疗与胰岛素抵抗相关的临床病症方面的用途，它们的治疗用途的方法以及包含它们的制药组合物。
• Benzoic acid derivatives as modulators of PPAR alpha and gamma
  申请人：AstraZeneca AB

  公开号：US07521461B2

  公开（公告）日：2009-04-21

  A compound of formula (I) wherein R1 represents aryl optionally substituted by a heterocyclic group or a heterocyclic group optionally substituted by aryl wherein each aryl or heterocyclic group is optionally substituted; the group —(CH2)m-T-(CH2)n—U—(CH2)p— is attached at either the 3 or 4 position in the phenyl ring as indicated by the numbers in formula (I) and represents a group selected from one or more of the following: O(CH2)2, O(CH2)3, NC(O)NR4(CH2)2, CH2S(O2)NR5(CH2)2, CH2N(R6)C(O)CH2, (CH2)2N(R6)C(O)(CH2)2, C(O)NR7CH2, C(O)NR7(CH2)2, and CH2N(R6)C(O)CH2O; V represents O, S, NR8 or a single bond; q represents 1, 2, or 3; W represents O, S, N(R9)C(O), NR10, or a single bond; R2 represents halo, a C1-4 alkyl group which is optionally substituted by one or more fluoro, a C1-4 alkoxy group which is optionally substituted by one or more fluoro, a C1-4 acyl group, aryl, an aryl C1-4 alkyl group, CN or NO2; r represents 0, 1, 2 or 3; R3 halo, a C1-4 alkyl group which is optionally substutited by one or more fluoro, a C1-4 alkoxy group which is optionally substituted by one or more fluoro, a C1-4 acyl group, aryl, an aryl C1-4 alkyl group, or CN; s represents 0, 1, 2 or 3; and R4, R5, R6, R7, R8, R9, and R10 independently represent H, a C1-10 alkyl group, aryl or an aryl C1-4 alkyl group or when m is O and T represents a group N(R6)C(O) or a group (R5)NS(O2) then R1 and R6 or R1 and R5 together with the nitrogen atom to which they are attached represent a heteroaryl group; with provisos and pharmaceutically acceptable salts thereof, processes for preparing such compounds, their utility in treating clinical conditions associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.

  化合物的式子(I)，其中R1代表取代了杂环基团或者取代了芳香基团的杂环基团，其中每个芳香基团或杂环基团都可以被取代；在苯环中，根据式子(I)中的数字，-（CH2）m-T-（CH2）n-U-（CH2）p-基团连接在3号或4号位置，表示从以下一种或多种基团中选择：O（CH2）2，O（CH2）3，NC（O）NR4（CH2）2，CH2S（O2）NR5（CH2）2，CH2N（R6）C（O）CH2，（CH2）2N（R6）C（O）（CH2）2，C（O）NR7CH2，C（O）NR7（CH2）2和CH2N（R6）C（O）CH2O；V代表O、S、NR8或单键；q代表1、2或3；W代表O、S、N（R9）C（O）、NR10或单键；R2代表卤素、C1-4烷基，其可以被一个或多个氟代取代，C1-4烷氧基，其可以被一个或多个氟代取代，C1-4酰基，芳香基团，芳香基团C1-4烷基，CN或NO2；r代表0、1、2或3；R3代表卤素、C1-4烷基，其可以被一个或多个氟代取代，C1-4烷氧基，其可以被一个或多个氟代取代，C1-4酰基，芳香基团，芳香基团C1-4烷基或CN；s代表0、1、2或3；R4、R5、R6、R7、R8、R9和R10独立地代表H、C1-10烷基，芳香基团或芳香基团C1-4烷基，或当m为O且T代表N（R6）C（O）或（R5）NS（O2）基团时，R1和R6或R1和R5与它们连接的氮原子一起表示杂芳基团；以及其药学可接受的盐、制备这样的化合物的方法，它们在治疗与胰岛素抵抗相关的临床病症方面的用途，它们的治疗用途的方法以及包含它们的制药组合物。
• US7521461B2
  申请人：——

  公开号：US7521461B2

  公开（公告）日：2009-04-21
• [EN] BENZOIC ACID DERIVATIVES AS MODULATORS OF PPAR ALPHA AND GAMMA<br/>[FR] DERIVES D'ACIDE BENZOIQUE UTILISES EN TANT QUE MODULATEURS DE PPAR ALPHA AND GAMMA
  申请人：ASTRAZENECA AB

  公开号：WO2004000295A1

  公开（公告）日：2003-12-31

  A compound of formula (I) wherein R1 represents aryl optionally substituted by a heterocyclic group or a heterocyclic group optionally substituted by aryl wherein each aryl or heterocyclic group is optionally substituted; the group -(CH2)m-T-(CH2)n-U-(CH2)p- is attached at either the 3 or 4 position in the phenyl ring as indicated by the numbers in formula (I) and represents a group selected from one or more of the following: O(CH2)2, O(CH2)3, NC(O)NR4(CH2)2 , CH2S(O2)NR5(CH2)2, CH2N(R6)C(O)CH2, (CH2)2N(R6)C(O)(CH2)2 , C(O)NR7 CH2 , C(O)NR7(CH2 )2 , and CH2N(R6)C(O)CH2O; V represents O, S, NR8, or a single bond;q represents 1, 2 or 3 ; W represents O, S, N(R9)C(O) , NR10,or a single bond;R2 represents halo, a C 1-4 alkyl group which is optionally substituted by one or more fluoro, a C 1-4 alkoxy group which is optionally substituted by one or more fluoro, a C 1-4 acyl group, aryl, an aryl C 1-4 alkyl group, CN or NO2 ; r represents 0, 1, 2 or 3 ; R3 represents halo, a C 1-4 alkyl group which is optionally substituted by one or more fluoro, a C 1-4 alkoxy group which is optionally substituted by one or more fluoro, a C 1-4 acyl group, aryl, an aryl C 1-4 alkyl group, or CN ; s represents 0, 1, 2 or 3 ; and R4, R5, R6 , R7, R8 , R9 and R10 independently represent H, a C 1-10 alkyl group, aryl or an aryl C 1-4 alkyl group or when m is 0 and T represents a group N(R6)C(O) or a group (R5)NS(O2) then R1 and R6 or R1 and R5 together with the nitrogen atom to which they are attached represent a heteroaryl group; with provisos and pharmaceutically acceptable salts thereof, processes for preparing such compounds, their utility in treating clinical conditions associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.

  式（I）的化合物，其中R1代表芳基，可选地被杂环基取代，或者被芳基取代的杂环基，其中每个芳基或杂环基可选地被取代；在苯环中的3位或4位之一连接有组-(CH2)m-T-(CH2)n-U-(CH2)p-，如式（I）中的数字所示，并表示从以下一个或多个中选择的组：O(CH2)2，O(CH2)3，NC(O)NR4(CH2)2，CH2S(O2)NR5(CH2)2，CH2N(R6)C(O)CH2，(CH2)2N(R6)C(O)(CH2)2，C(O)NR7CH2，C(O)NR7(CH2)2和CH2N(R6)C(O)CH2O；V代表O，S，NR8或单键；q代表1、2或3；W代表O，S，N(R9)C(O)，NR10或单键；R2代表卤素，可选地被一个或多个氟取代的C1-4烷基，可选地被一个或多个氟取代的C1-4烷氧基，C1-4酰基，芳基，芳基C1-4烷基，CN或NO2；r代表0、1、2或3；R3代表卤素，可选地被一个或多个氟取代的C1-4烷基，可选地被一个或多个氟取代的C1-4烷氧基，C1-4酰基，芳基，芳基C1-4烷基或CN；s代表0、1、2或3；R4、R5、R6、R7、R8、R9和R10独立地代表H，C1-10烷基，芳基或芳基C1-4烷基，或者当m为0且T代表N(R6)C(O)或(R5)NS(O2)时，R1和R6或R1和R5与它们连接的氮原子一起代表杂芳基；以及其药学上可接受的盐，制备这种化合物的方法，它们在治疗与胰岛素抵抗相关的临床病症中的用途，它们的治疗用途的方法和含有它们的药物组合物。